“…We chose curcumin (CUR) as polyphenol moiety because of its well-known biological properties and ability to be used in combination chemotherapy protocols for the treatment of a wide number of cancer diseases with high efficiency [17,18]. In the literature, different CUR-polymer conjugates (e.g., xylan [19], hyaluronic acid [20], chitosan [21], Dextran [22], PEG [23], and albumin [24]) were reported with the purpose to improve the anticancer performance of the polyphenol and to synergize conventional chemotherapeutics such as methotrexate (MTX), doxorubicin, and paclitaxel. Herein, we propose the enzymatic conjugation of CUR to Dextran (DEX-CUR), a glucose homopolysaccharide showing high biocompatibility and chemical versatility [25], in order to transfer the biological activity of CUR to a macromolecular systems able to self-assembly (DC), encapsulate, and control the release of MTX.…”